Kilian Schiller1, Michael Geier1,2, Marciana Nona Duma1,3, Carsten Nieder4,5, Michael Molls1, Stephanie E Combs1,6,7, Hans Geinitz1,2. 1. Klinik und Poliklinik für Strahlentherapie und RadioOnkologie, Technische Universität München, München, Germany. 2. Abteilung für Radioonkologie; Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria. 3. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum, Friedrich-Schiller-Universität, Jena, Germany. 4. Department of Oncology and Palliative Care, Nordland Hospital, Nordland Hospital Trust, Bodø, Norway. 5. Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. 6. Institut für Innovative Radiotherapie (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München (HMGU), Oberschleißheim, Germany. 7. Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany.
Abstract
AIM: To report long-term data regarding biochemical control and late toxicity of simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT) with tomotherapy in patients with localized prostate cancer. BACKGROUND: Dose escalation improves cancer control after curative intended radiation therapy (RT) to patients with localized prostate cancer, without increasing toxicity, if IMRT is used. MATERIALS AND METHODS: In this retrospective analysis, we evaluated long-term toxicity and biochemical control of the first 40 patients with intermediate risk prostate cancer receiving SIB-IMRT. Primary target volume (PTV) 1 including the prostate and proximal third of the seminal vesicles with safety margins was treated with 70 Gy in 35 fractions. PTV 2 containing the prostate with smaller safety margins was treated as SIB to a total dose of 76 Gy with 2.17 Gy per fraction. Toxicity was evaluated using an adapted CTCAE-Score (Version 3). RESULTS: Median follow-up of living patients was 66 (20-78) months. No late genitourinary toxicity higher than grade 2 has been reported. Grade 2 genitourinary toxicity rates decreased from 58% at the end of the treatment to 10% at 60 months. Late gastrointestinal (GI) toxicity was also moderate, though the prescribed PTV Dose of 76 Gy was accepted at the anterior rectal wall. 74% of patients reported any GI toxicity during follow up and no toxicity rates higher than grade 2 were observed. Grade 2 side effects were reported by 13% of the patients at 60 months. 5-year freedom from biochemical failure was 95% at our last follow up. CONCLUSION: SIB-IMRT using daily MV-CT guidance showed excellent long-term biochemical control and low toxicity rates.
AIM: To report long-term data regarding biochemical control and late toxicity of simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT) with tomotherapy in patients with localized prostate cancer. BACKGROUND: Dose escalation improves cancer control after curative intended radiation therapy (RT) to patients with localized prostate cancer, without increasing toxicity, if IMRT is used. MATERIALS AND METHODS: In this retrospective analysis, we evaluated long-term toxicity and biochemical control of the first 40 patients with intermediate risk prostate cancer receiving SIB-IMRT. Primary target volume (PTV) 1 including the prostate and proximal third of the seminal vesicles with safety margins was treated with 70 Gy in 35 fractions. PTV 2 containing the prostate with smaller safety margins was treated as SIB to a total dose of 76 Gy with 2.17 Gy per fraction. Toxicity was evaluated using an adapted CTCAE-Score (Version 3). RESULTS: Median follow-up of living patients was 66 (20-78) months. No late genitourinary toxicity higher than grade 2 has been reported. Grade 2 genitourinary toxicity rates decreased from 58% at the end of the treatment to 10% at 60 months. Late gastrointestinal (GI) toxicity was also moderate, though the prescribed PTV Dose of 76 Gy was accepted at the anterior rectal wall. 74% of patients reported any GI toxicity during follow up and no toxicity rates higher than grade 2 were observed. Grade 2 side effects were reported by 13% of the patients at 60 months. 5-year freedom from biochemical failure was 95% at our last follow up. CONCLUSION: SIB-IMRT using daily MV-CT guidance showed excellent long-term biochemical control and low toxicity rates.
Entities:
Keywords:
Fractionation; Late toxicity; Long term follow up; Prostate Cancer; Rectal toxicity; Tomotherapy
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Heidi T Lotz; Peter Remeijer; Marcel van Herk; Joos V Lebesque; Josien A de Bois; Lambert J Zijp; Luc M Moonen Journal: Med Phys Date: 2004-06 Impact factor: 4.071
Authors: Irene M Lips; Homan Dehnad; Carla H van Gils; Arto E Boeken Kruger; Uulke A van der Heide; Marco van Vulpen Journal: Radiat Oncol Date: 2008-05-21 Impact factor: 3.481
Authors: Di Cui; Lei Du; Wei Yu; Boning Cai; Lingling Meng; Jun Yang; Yanrong Luo; Jing Chen; Lin Ma Journal: Radiol Oncol Date: 2022-03-28 Impact factor: 4.214